FORA Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

FORA Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-18,585	Closed	-$3.41M	–	1006
2021 Q2	$3.41M	Buy	+18,585	New	+$3.19M	0.64%	28
2021 Q1	–	Sell	-25,725	Closed	-$4.02M	–	1238
2020 Q4	$4.02M	Buy	25,725 +24,426	+1,880%	+$3.14M	0.61%	31
2020 Q3	$149K	Sell	1,299 -6,637	-84%	-$716K	0.1%	222
2020 Q2	$891K	Buy	7,936 +1,264	+19%	+$134K	0.31%	78
2020 Q1	$599K	Buy	+6,672	New	+$655K	0.13%	207

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

FORA Capital's ALXN Position: Q3 2021 in Review

FORA Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 18,585 shares — an estimated $3.41M sold.

FORA Capital first reported a position in ALXN in Q1 2020 and held it in 5 quarters. The position peaked at $4.02M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

FORA Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
FORA Capital sold 18,585 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.41M.
FORA Capital first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 5 quarters.
FORA Capital's Alexion Pharmaceuticals position peaked at $4.02M in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on FORA Capital's 13F filing for Q3 2021, filed 15 Nov 2021.